TITLE:
Single Nucleotide Polymorphisms (SNPs) of URAT1 (rs7932775) and ABCG2 (rs3825016) on Chronic Kidney Disease Patients with Hyperuricemia
AUTHORS:
Chunqing Li, Qiong Tang, Hongwei Jiang, Jing Wu, Junlin Zhang, Fenglai Yuan, Yuan Du, Haochang Du
KEYWORDS:
Hyperuricemia, Chronic Kidney Disease (CKD), Single Nucleotide Polymorphisms (SNP), Human Urate Transport Protein (Hurat1), ATP Binding Transporter G Super Family (ABCG2)
JOURNAL NAME:
Chinese Medicine,
Vol.9 No.3,
August
2,
2018
ABSTRACT: Background: More and more chronic kidney disease (CKD) patients
are accompanied with hyperuricaemia. As is known, hyperuricaemia is an
independent hazard of both cardiovascular diseases (CVD) and chronic kidney
diseases. We aim at identifying Single Nucleotide Polymorphism (SNP) difference
of hURAT1 (rs7932775) and ABCG2 (rs3825016) on CKD patient with hyperuricemia
and/or gout. Methods: All forty-two CKD patients were divided into two
groups: hyperuricemia, and control group. 24 hours urine sample and serum were prepared for testing
biochemistry parameters. The polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method is used to analyze hURAT1 and ABCG2 single nucleotide polymorphisms in
different groups. Results: 17 patients have CT SNP of hURAT1 (rs7932775) and 13 patients have CT SNP
of ABCG2 (rs3825016) in hyperuricemia group, while only 5 persons and 6 persons
have the same mutations in control group respectively. 7 patients have CT SNP
of both hURAT1 (rs7932775) and ABCG2 (rs3825016) in hyperuricemia group, while
only 2 persons have the same mutations in control group. CT mutation rates of hURAT1 (rs7932775) and ABCG2
(rs3825016) in hyperuricemia group were 60.7% (17/28) and 50% (13/28) respectively, higher than that of control
group (35.7% (5/14)
and 42.8% (6/14)).
What is more, Double SNP mutations in both hURAT1 (rs7932775) and ABCG2
(rs3825016) in hyperuricemia group were 25% (7/28), higher than that of control group (14.2%, 2/14). Conclusion: There are higher mutation rates of CT SNP in hURAT1 (rs7932775) and/or
ABCG2 (rs3825016) in hyperuricemia group. We can conclude that hyperuricemia is
a high risk factor in progress of CKD, which is necessary to take measures of
decreasing serum uric acid to delay CKD progress.